
## **Chih-Ling Chung**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9744565/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recent progress in TGF-β inhibitors for cancer therapy. Biomedicine and Pharmacotherapy, 2021, 134, 111046.	5.6	77
2	Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma. Biochemical Pharmacology, 2018, 154, 39-53.	4.4	21
3	Pentabromophenol suppresses TGF-Î <sup>2</sup> signaling by accelerating degradation of type II TGF-Î <sup>2</sup> receptors via caveolae-mediated endocytosis. Scientific Reports, 2017, 7, 43206.	3.3	17
4	Pentachloropseudilin Inhibits Transforming Growth Factorâ€Î² (TGFâ€Î²) Activity by Accelerating Cellâ€&urface Type II TGFâ€Î² Receptor Turnover in Target Cells. ChemBioChem, 2018, 19, 851-864.	2.6	16
5	Roles of Myosin-Mediated Membrane Trafficking in TGF-β Signaling. International Journal of Molecular Sciences, 2019, 20, 3913.	4.1	10